- Home
- VSTM vs KURA Comparison
VSTM vs KURA Comparison
Compare VSTM & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- KURA
- Stock Information
- Founded
- VSTM 2010
- KURA 2014
- Country
- VSTM United States
- KURA United States
- Employees
- VSTM N/A
- KURA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTM Health Care
- KURA Health Care
- Exchange
- VSTM Nasdaq
- KURA Nasdaq
- Market Cap
- VSTM 425.9M
- KURA 492.9M
- IPO Year
- VSTM 2012
- KURA N/A
- Fundamental
- Price
- VSTM $6.06
- KURA $6.19
- Analyst Decision
- VSTM Strong Buy
- KURA Strong Buy
- Analyst Count
- VSTM 9
- KURA 12
- Target Price
- VSTM $13.63
- KURA $24.50
- AVG Volume (30 Days)
- VSTM 2.1M
- KURA 1.2M
- Earning Date
- VSTM 05-13-2025
- KURA 05-01-2025
- Dividend Yield
- VSTM N/A
- KURA N/A
- EPS Growth
- VSTM N/A
- KURA N/A
- EPS
- VSTM N/A
- KURA N/A
- Revenue
- VSTM $10,000,000.00
- KURA $67,991,000.00
- Revenue This Year
- VSTM $106.87
- KURA $171.90
- Revenue Next Year
- VSTM $312.95
- KURA $60.51
- P/E Ratio
- VSTM N/A
- KURA N/A
- Revenue Growth
- VSTM N/A
- KURA N/A
- 52 Week Low
- VSTM $2.10
- KURA $5.41
- 52 Week High
- VSTM $9.10
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- VSTM 47.31
- KURA 47.97
- Support Level
- VSTM $7.60
- KURA $5.56
- Resistance Level
- VSTM $9.10
- KURA $5.84
- Average True Range (ATR)
- VSTM 0.88
- KURA 0.34
- MACD
- VSTM -0.09
- KURA -0.00
- Stochastic Oscillator
- VSTM 33.16
- KURA 43.69
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.